C.R. Bard
http://www.crbard.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From C.R. Bard
South Korea Sees Pharma Leadership Transition
Leadership succession is proceeding within South Korean pharmaceutical corporations such as Daiichi Sankyo Korea, Astellas Pharma Korea, Kyowa Kirin Korea as well as MSD Korea.
Boehringer’s Slashed Cyltezo Salesforce Reflects Struggles For US Humira Biosimilars
Boehringer Ingelheim’s decision not only reflects the company’s difficulties in gaining traction for the first interchangeable version of adalimumab, but also the wider problems for Humira biosimilars in the US.
Samsung Bioepis Kicks Off Phase III Pembrolizumab Trial
Samsung Bioepis has begun Phase III trials for its SB27 proposed pembrolizumab biosimilar to Keytruda – although the firm is just one of many developers eyeing the opportunity.
Samsung Bioepis’ Stelara Biosimilar Shows Long-Term Similarity In Plaque Psoriasis
Hot off the press, Samsung Bioepis reports final data for its ustekinumab biosimilar SB17 in plaque psoriasis ahead of potential US market entry early next year, and gives more data on adalimumab biosimilar Hadlima to support interchangeability.
Company Information
- Industry
- Medical Devices
- Other Names / Subsidiaries
-
- Davol, Inc.
- Embo Medical Limited
- Liberator Medical, Inc.
- Lutonix, Inc.
- Medafor, Inc.
- Medicon, Inc.
- Neomend, Inc.
- Rochester Medical, Inc.
- Vascular Pathways, Inc.
- FlowCardia, Inc.
- Bridger Biomed, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice